Clinical trial
A Randomised, Single-centre, Double-blind, Cross-over Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counter-regulation Compared to Placebo in Subjects With Type 2 Diabetes
NCT02147431 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Single-centre, Double-blind, Cross-over Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counter-regulation Compared to Placebo in Subjects With Type 2 Diabetes
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 21, 2014
- Completion date
- May 20, 2015
- Enrollment
- 38 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diabetes, diabetes mellitus, type 2